You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage II adult diffuse mixed cell lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin's, Adult Trial in Rosario, Caba (Evaluation of first line treatment in patients with stage I and II LBCL)

Recruiting
  • Lymphoma, Non-Hodgkin's, Adult
  • Evaluation of first line treatment in patients with stage I and II LBCL
  • Paraná, Entre Ríos, Argentina
  • +6 more
Dec 29, 2022

Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • loncastuximab tesirine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Jun 24, 2022

Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

Completed
Has Results
  • Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Campath
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022

Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
Oct 26, 2022

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

DLBCL Trial in Japan (MT-2111)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Nagoya-shi, Aichi, Japan
  • +3 more
Jan 12, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

EBV-Positive DLBCL, Nos Trial in Guangzhou, Shanghai (Selinexor, R-CHOP Protocol)

Recruiting
  • EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
  • Guangzhou, Guangdong, China
  • +1 more
Nov 10, 2022

Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)

Active, not recruiting
  • Diffuse Large B-cell-lymphoma
  • Saint Louis, Missouri
  • +2 more
Nov 14, 2022

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Adult Patients Who Initiate Systemic Treatment for

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional
  • Graz, Austria
  • +8 more
Sep 19, 2022

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Aug 22, 2022

Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Trial in United States

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Mogamulizumab
  • Pembrolizumab
  • Sacramento, California
  • +7 more
Sep 15, 2022

Lymphoma Trial in Scottsdale, Jacksonville, Rochester (biological, drug, genetic, other)

Active, not recruiting
  • Lymphoma
  • pegfilgrastim
  • +8 more
  • Scottsdale, Arizona
  • +2 more
Jan 7, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial

Completed
Has Results
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • +9 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
  • +7 more
Nov 4, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Diffuse Large Cell Lymphoma Relapsed/Refractory Trial in San Francisco (Ofatumumab, Etoposide, Cytarabine)

Completed
Has Results
  • Diffuse Large Cell Lymphoma Relapsed/Refractory
  • San Francisco, California
    University of California, San Francisco
Jun 5, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022